Background: Gemtuzumab ozogamicin (GO) was approved in 2017 in the US for the treatment of adults with newly diagnosed CD33-positive (CD33+) acute myeloid leukemia (AML), and adults and pediatric patients with CD33+ relapsed/refractory (R/R) AML.
Objective: The aim of this study was to estimate the budgetary impact of introducing GO to a 1-million-member US health plan over a 5-year period.
Methods: We developed models to estimate the impact of introducing GO in combination with conventional induction chemotherapy or as monotherapy for newly diagnosed AML, and as monotherapy for R/R AML. Models were built using data on drug costs and treatment-related outcomes obtained from published clinical trials and other publicly available sources. Results were reported on a per member/per year and per member/per month (PMPM) basis.
Results: Base-case results of the newly diagnosed model indicated that the addition of GO in the combination setting reduced the overall budget of a 1-million-member health plan. The estimated net cost (US$) savings ranged from $72,969 ($0.006 PMPM) in year 1 to $745,426 ($0.062 PMPM) in year 5. In the monotherapy setting, GO was associated with increased net costs ranging from $4118 (0.0003 PMPM) in year 1 to $31,885 ($0.003 PMPM) in year 5. Base-case results of the R/R AML model demonstrated increased net costs that ranged from $17,326 ($0.001 PMPM) in year 1 to $46,163 ($0.004 PMPM) in year 5. Scenario analyses in all settings indicated the budget impact was not overly sensitive to the selected input assumptions, with the exception of the scenario considering only the pharmacy budget impact in the combination setting.
Conclusions: The introduction of GO for newly diagnosed and R/R AML would have a minimal impact on the budget of a US health plan and could result in cost savings in the combination therapy setting for newly diagnosed AML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790788 | PMC |
| http://dx.doi.org/10.1007/s40273-020-00976-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A US payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease.
J Med Econ
December 2024
GE HealthCare Inc, Marlborough, MA, USA.
Aims: This economic model was developed to assess the budget impact of a novel radiotracer, Flurpiridaz (F-PET-MPI), compared to SPECT-MPI from a US payer perspective.
Materials And Methods: The model was developed comparing F-PET-MPI and SPECT-MPI, with F-PET-MPI modality share increasing from 0.5% to 2.
Improving Adherence and Reducing Health Care Costs Through Blister-Packaging: An Economic Model for a Commercially Insured Health Plan.
Clinicoecon Outcomes Res
October 2024
Health Economics & Outcomes Research (HEOR), Becton, Dickinson and Company, Franklin Lakes, NJ, USA.
Purpose: To model the potential clinical and economic impact of blister-packaging medications for chronic conditions on medication adherence and healthcare costs in a commercially insured population.
Methods: A health economic model was developed to evaluate the potential impact of blister-packaging chronic medications for a commercially insured population. The chronic medication classes assessed were renin-angiotensin-system (RAS) antagonists, statins, non-insulin oral antidiabetics, and direct oral anticoagulants (DOACs).
Article Synopsis
- The study aims to estimate the budget impact of adding toripalimab to the treatment options for patients with advanced nonsquamous NSCLC, comparing costs without and with this new regimen over three years.
- A budget impact analysis was conducted, assessing the costs of treatment, administration, and management of adverse events, focusing on a large population of patients and utilizing different price inputs for the medications.
- Results showed that incorporating toripalimab leads to significant cost savings, with projected annual savings ranging from about $10.8 million in the first year to nearly $64.9 million in the third year, indicating that treating even a small percentage of patients could be financially beneficial.
Association between depression symptom severity and total cost of care: Findings from a large, 2-year, claims-based, retrospective population health study.
J Affect Disord
January 2025
Highmark Health, Pittsburgh, PA, USA; Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Background: Despite the substantial impact of depression on individuals and healthcare utilization, little is known about the specific relationship between depression severity and total cost of care (TCC). This study evaluates the association between depression symptom severity and TCC and how changes in severity affect TCC.
Methods: The analysis was conducted using insurance claims data and data from electronic health records between January 1, 2019 and December 31, 2020.
Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.
J Med Econ
September 2024
Value Evidence & Outcomes, GSK, Collegeville, PA, USA.
Aim: Dostarlimab plus carboplatin-paclitaxel (CP) significantly increased progression-free survival in patients with primary advanced or recurrent endometrial cancer (pA/rEC) vs CP alone in the RUBY trial (NCT03981796). This analysis estimated the per-member-per-month (PMPM) costs of introducing dostarlimab + CP as a treatment alternative from a third-party US payer perspective.
Materials And Methods: A budget impact model was developed to estimate the costs of introducing dostarlimab + CP into commercial and Medicare health plans over a 3-year time horizon (2023-2025).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!